Recapping just some of the notable data coming out of ESMO 2024:-Final OS results from Keynote-522 (perioperative pembrolizumab in TNBC)-AMBASSADOR (adjuvant pembrolizumab in bladder cancer) -NIAGRA (perioperative durvalumab in bladder cancer)-ADRIATIC (discussed on ASCO recap Pod, but publication now available)-LEANOX (impact of lean body mass adjustment on oxaliplatin dose)